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Abstract
Background—Prior administration of a small dose of lipopolysaccharide confers a cardiac
protection against ischemia-reperfusion injury. However, the signaling mechanisms that control
the protection are incompletely understood. We tested the hypothesis that TLR4 mediates the
ability of lipopolysaccharide to protect against cardiac ischemia-reperfusion injury through distinct
intracellular pathways involving myeloid differentiation factor 88 (MyD88), TIR-domain-
containing adaptor protein inducing interferon-β–mediated transcription-factor (Trif), inducible
nitric-oxide synthase (iNOS), and soluble guanylate cyclase (sGC).
Methods—Wild-type mice and the genetically modified mice, i.e., TLR4-deficient (TLR4-def),
TLR2 knockout (TLR2−/−), MyD88−/−, Trif−/−, iNOS−/−, and sGCα1−/−, were treated with
normal saline or 0.1 mg/kg of lipopolysaccharide, intraperitoneally. Twenty-four hours later,
isolated hearts were perfused in a Langendorff apparatus and subsequently subjected to 30 min of
global ischemia and reperfusion for up to 60 min. Left ventricular function and myocardial
infarction sizes were examined.
Results—Compared to saline-treated mice, lipopolysaccharide-treated mice had markedly
improved left ventricular developed pressure and dP/dtmax (P < 0.01) and reduced MI sizes (37.2
± 3.4% vs. 19.8 ± 4.9%, P < 0.01) after ischemia-reperfusion. The cardiac protective effect of
lipopolysaccharide was abolished in the TLR4-def and MyD88−/− mice, but remained intact in
TLR2−/− or Trif−/− mice. iNOS−/− mice or wild-type mice treated with the iNOS inhibitor 1400W
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failed to respond to the TLR4-induced nitric oxide production and were not protected by the
lipopolysaccharide preconditioning. While sGC 1−/− mice had robust nitric oxide production in
response to lipopolysaccharide, they were not protected by the TLR4-elicited cardiac protection.
Conclusions—TLR4 activation confers a potent cardiac protection against ischemia-reperfusion
injury via a MyD88-dependent, but Trif-independent mechanism. iNOS/sGC are essential for the
TLR4-induced cardiac protection.
INTRODUCTION
Toll-like receptors (TLRs) represent the first line of host defense against microbial infection
and play a pivotal role in both innate and adaptive immunity 1. TLRs recognize invading
pathogens through the “molecular pattern-recognition”, transduce the signals via distinct
intracellular pathways involving a unique set of adaptor proteins and kinases, and ultimately
lead to activation of transcription factors and inflammatory responses 2,3. All TLRs, except
TLR3, signal through the common MyD88-dependent pathway. TLR3 signals exclusively,
and TLR4 partly via MyD88-independent but Trif-dependent pathway 4,5. Animal studies
have indicated that these receptors are in part responsible for cardiac dysfunction in certain
pathological conditions characterized in either Gram-negative or Gram-positive bacterial
infection, such as endotoxemia 6,7, peptidoglycan-associated lipoprotein 8, staphylococcus
aureus 9, and in polymicrobial peritonitis 10.
In addition to their role in mediating cardiac dysfunction in septic conditions, emerging
evidence indicate that TLRs may also play an important role in noninfectious tissue injury in
various organs including the heart and liver 5,11. In the heart, for example, systemic
deficiency of TLR2, TLR4, or MyD88 leads to attenuated myocardial inflammation, smaller
infarction size, and better preserved ventricular function after transient ischemic injury 12–
17. These loss-of-function studies suggest that the intrinsic TLR signaling may contribute to
myocardial inflammation and injury during ischemia-reperfusion (I/R).
Intriguingly, a large body of evidence in several animal models demonstrates that prior
administration of sub-lethal dose of lipopolysaccharide confers a “preconditioning-like”
effect [Review: Ref. 5], similar to the well-characterized ischemic preconditioning 18 or
anesthetic preconditioning 19, protecting the heart against subsequent lethal I/R injury. The
cardioprotective effect of lipopolysaccharide usually occurs between 12 – 24 h after
administration of lipopolysaccharide and is abolished by cycloheximide, a protein synthesis
inhibitor that blocks translation elongation, suggesting a mechanism involving de novo
synthesis of cardioprotective proteins 20. Lipopolysaccharide is known to enhance
production of inducible nitric-oxide synthase (iNOS) in the heart, a process mediated via
TLR4 7,21. We have previously demonstrated, in an in vitro system, that TLR4 activation by
lipopolysaccharide leads to a survival benefit in isolated cardiomyocytes through MyD88-
and iNOS-dependent mechanisms 21,22. iNOS has also been proposed to be the trigger for
the lipopolysaccharide-induced preconditioning 23. However, given the multiple systemic
reactions in response to in vivo administration of lipopolysaccharide in these animal studies,
it is unclear whether the observed cardiac benefits are the direct results of TLR4 stimulation
or due to other events secondary to systemic TLR4 activation. Therefore, the critical role of
TLR4 and its downstream signaling events in the cardiac protection in vivo remains unclear.
Here, we tested the hypothesis that TLR4 specifically mediates the lipopolysaccharide-
elicited cardiac protection against I/R injury through distinct intracellular pathways
involving MyD88, Trif, iNOS, and sGC. Using genetically modified mice and an ex-vivo
model of I/R injury, we demonstrate that TLR4-MyD88 signaling confers a potent cardiac
protection against I/R injury via iNOS- and sGC-dependent mechanisms.
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MATERIALS AND METHODS
Animals
C57BL/6J, C57BL/10ScSn, iNOS−/−/C57BL/6J, and TLR4-def mice (C57BL/10ScCr) were
purchased from The Jackson Laboratory (Bar Harbor, ME). C57BL/10ScCr is also referred
to as C57BL/10ScNJ (Stock No. 003752) with wild-type (WT) Il12rb2 allele. C57BL/
10ScCr mice have a deletion of the Tlr4 gene that results in absence of both mRNA and
protein and thus in defective response to lipopolysaccharide stimulation. Tlr4lps-del differs
from the Tlr4Lps-d mutation of C3H/HeJ mice, a point mutation of Tlr4 gene that causes an
amino acid substitution 24. C57BL/10ScSn mice were used as the appropriate WT controls
for the TLR4-def mice. TLR2−/− mice were generated by Takeuchi et al 25. MyD88−/− mice
were generated by Kawai and colleagues 26 and had been backcrossed > 10 generations into
the C57BL/6J strain. Trif−/− mice were generated by Yamamoto, et al. 27. sGCα1−/− mice
were generated on the 129S6 background (sGCα1−/−S6) and were backcrossed at least eight
generations into a C57BL/6J background (sGCα1−/−B6) 28. sGCα1−/− mice carry a targeted
deletion of the sixth exon of the gene encoding of a mutant, catalytically inactive protein.
All mice used in the sGC 1, resulting in the expression study were 8–12 week-old, male
(except sGCα1−/−B6 mice), and weighed between 20–30 g. Mice were fed with the same
bacteria-free diet (Prolab Isopro RMH 3000) and water, and housed in accordance with
guidelines from the American Association for Laboratory Animal Science (Memphis, TN).
All animal protocols used in the study were approved by the Subcommittee on Research
Animal Care of the Massachusetts General Hospital (Boston, Massachusetts).
Lipopolysaccharide treatment
WT and the genetically modified mice were treated with normal saline or lipopolysaccharide
(Escherichia coli 0111:B4, Sigma, St Louis, MO) at the dose of 0.1mg/kg by intraperitoneal
injection 24 h prior to the I/R protocol. Lipopolysaccharide was dissolved in normal saline
and diluted to a final concentration of 0.02 mg/ml for intraperitoneal injection. Baseline left
ventricular (LV) function was examined with echocardiography and catheter-based LV
pressure measurement in both normal saline- and lipopolysaccharide-treated mice prior to
the ex-vivo I/R protocol. To test the effect of iNOS inhibition, WT C57BL/6J mice were
injected with 1400W (20 mg/kg) (Enzo Life Sciences International, Plymouth Meeting, PA),
intraperitoneally, 2 hours before lipopolysaccharide treatment. 1400W or N-(3-
(Aminomethyl)benzyl)acetamidine is a slow, tight binding, and highly selective inhibitor of
iNOS 29. It is at least 5,000- and 1,000-folds selective for iNOS versus endothelial NOS
(eNOS) in vitro assay and in isolated rat aortic rings, respectively. Inhibition of neuronal
NOS (nNOS) and eNOS by 1400W was weaker and rapidly reversible. In the original in
vivo study, 1400W at 5 mg/kg inhibited lipopolysaccharide-induced vascular leakage by
94% 29.
Echocardiographic measurements
Twenty-four hours after lipopolysaccharide administration, mice were lightly anesthetized
with ketamine (20 mg/kg). Transthoracic echocardiographic images were obtained and
interpreted by an echocardiographer blinded to the experimental design using a 13.0-MHz
linear probe (Vivid 7; GE Medical System, Milwaukee, WI) as described previously 10,16.
M-mode images were obtained from a parasternal short-axis view at mid-ventricular level
with a clear view of papillary muscle. LV end-diastolic internal diameter (LVIDED) and LV
end-systolic internal diameter (LVIDES) were measured. Fractional shortening (FS) was
defined as [(LVIDED – LVIDES)/LVIDED] × %. Ejection fraction (EF) was calculated by the
formula (EDV-ESV)/EDV × %, in which EDV was defined as 7 × LVIDED3/(2.4+ LVIDED)
or area-length method in 2-D long axis view, ESV was defined as 7 × LVIDES3/(2.4+
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LVIDES) or area-length method in 2-D long axis view. The values of three consecutive
cardiac cycles were averaged.
Ex vivo model of myocardial ischemia/reperfusion injury
The aorta was cannulated and the hearts perfused in a Langendorff apparatus as described
previously with minor modifications 10,16. Isolated hearts were perfused at a constant
pressure of 80 mmHg with modified Krebs-Henseleit buffer containing 118 mM NaCl, 24
mM NaHCO3, 10 mM glucose, 4.7 mM KCl, 1.2 mM KH2PO4, 1.2 mM MgSO4, 2.5 mM
CaCl2, and 2 mM pyruvate, pH 7.4, at 37 °C. The perfusate was saturated with continuous
gas flow consisting of 95% O2 and 5% CO2. A balloon was made with wrapped saran film
connected to a PE-50 polyethylene tube. The neck to tip distance of the balloon was about
6–7 mm. The balloon was inserted into the LV chamber through the mitral valve with an
incision in the left atrium, and was connected to a pressure transducer (APT300, Harvard
Apparatus, Holliston, MA) for continuous measurement of LV pressure. The balloon was
inflated with deionized water (15 – 20 μl) to adjust LV end-diastolic pressure (LVEDP) to
6–10 mmHg. The perfused hearts were then immersed in the perfusate maintained at 37 ±
0.5 °C and paced at 420 beats/min with pacing electrodes placed on the right atrium. After a
30 min of constant pressure perfusion, the hearts were subjected to 30 min of zero-flow
ischemia followed by reperfusion for 60 min. Pacing was interrupted during ischemia and
resumed 3 min after the start of reperfusion. LV Function data were recorded continuously
on a data acquisition system (PowerLab, AD Instruments, Colorado Springs, CO). LV
developed pressure (LVDP) was calculated as the difference between peak-systolic pressure
and LVEDP. dP/dt max was calculated as the maximum rate of increase of LVDP. The
recovery of the LV function during the reperfusion was expressed as the percentage of the
baseline LVDP and dP/dt max, which were recorded prior to the ischemic phase.
Determination of MI sizes
Infarct sizes were determined by triphenyltetrazolium chloride (TTC, Sigma) staining as
described previously 16,17. The hearts were removed from Langendorff device at the end of
reperfusion. Each heart was sliced into four sections. The myocardial sections were
incubated in 1% TTC in phosphate buffered saline for 15 min at 37 °C. The infarct area
(white) and noninfarct area (red) from each section were measured using an image analysis
program. Ratios of infarct area/left ventricle were calculated and expressed as the percentage
of LV (MI/LV × 100%).
Measurement of plasma nitrate/nitrite
The plasma nitrate/nitrite was measured according to the manusfacturer’s instructions of the
NOx fluorometric assay kit (Cayman Chemical Company, Ann Arbor, MI). Briefly, the
plasma was filtered through 30 kDa molecular weight cut-off Amicon ultra centrifugal
filters (Millipore, Billerica, MA). Ten μl of appropriately diluted samples were incubated
with nitrate reductase and cofactor at room temperature for 2 h to convert nitrate to nitrite.
The assay mixture was then incubated with 10 μl of DAN reagent in the dark for 10 min.
The reaction was stopped by adding 20 μl of NaOH solution into the mixture. The
fluorescence was measured in a SpectraMax M5 (Molecular Devices, Sunnyvale, CA) with
an excitation of 360 nm and an emission of 430 nm. Nitrite concentrations in the plasma
samples were calculated from a standard curve.
Statistical Analysis
Statistical analysis was performed using Graphpad Prism 5 software (GraphPad, La Jolla,
CA). The distributions of the continuous variables were expressed as mean ± SE. For LVDP
and dP/dtmax data analysis, statistical significance of the difference between two groups
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(e.g., normal saline vs. lipopolysaccharide or WT vs. Knockout) at the different time points
was measured by two-way ANOVA with Bonferroni post hoc tests and repeated
measurements. Of note, these specific comparisons were made based on a priori hypotheses
rather than pure statistical considerations. Paired Students’ t-test was used for
echocardiographic data analysis, MI size, and nitrate/nitrite measurements. The null
hypothesis was rejected for P < 0.05.
RESULTS
Low dose (0.1 mg/kg) of lipopolysaccharide pretreatment improves LV function and
reduces MI sizes following I/R injury through a TLR4-dependent mechanism
Lipopolysaccharide is known for inducing cardiac dysfunction during endotoxemia. In mice,
at the doses of 5 mg/kg and 25 mg/kg, lipopolysaccharide induces significant LV contractile
dysfunction through a TLR4-dependent mechanism 7. To test if at a low dose (0.1 mg/kg),
lipopolysaccharide induces any LV dysfunction, mice were treated with either normal saline
or lipopolysaccharide by intraperitoneal injection. Cardiac function was assessed before and
24 h after the injection by echocardiography (fig. 1 and table 1) and by LV pressure
measurement (table 2). As indicated in figure 1 and table 1, 0.1 mg/kg of lipopolysaccharide
did not impact the LV function, nor did it change the LV chamber sizes. The saline- and
lipopolysaccharide-treated mice had similar EF, FS, and LVID before and 24 h after the
treatment. We also calculated the EF with the end diastolic/systolic volumes as measured by
area-length method in a 2-D long-axis view and confirmed that there was no difference
between the saline and LPS groups (data not shown).
Pretreatment with the low dose of lipopolysaccharide, however, conferred a marked cardiac
protection against I/R injury. As indicated in figure 2 A–B, after 30 min of ischemia and 60
min of reperfusion, LV function, as measured by LVDP and dP/dtmax, recovered to 47.6 ±
2.8% and 55.8 ± 4.4% of the baseline, respectively, in WT mice treated with saline (WTBL/
10-Saline) (n = 9/group). In comparison, the hearts isolated from the lipopolysaccharide-
treated mice (WTBL/10-lipopolysaccharide) exhibited significantly better LVDP (65.2 ±
5.6% at 60 min, P < 0.01) and dP/dtmax (89.8 ± 10.2% at 60 min, n = 8, P < 0.05) compared
to the WTBL/10-saline group. The significant difference between WTBL/10-Saline and
WTBL/10-LPS displayed as early as 10 min after reperfusion based on Bonferroni post hoc
test. In addition, 30 min of ischemia and 60 min of reperfusion resulted in significant
myocardial infarction in WT mice (MI/LV: 37.2 ± 3.4%, n = 8). lipopolysaccharide
pretreatment led to a marked reduction in MI sizes (19.8 ± 4.9%, n = 7 P < 0.05,) (fig. 2 C–
D). To determine whether TLR4 mediates the lipopolysaccharide-elicited cardiac protection,
we tested the lipopolysaccharide preconditioning in the TLR4-deficient mice (TLR4-def). As
indicated in figure 2, LVDP, dP/dtmax, and MI sizes after 30 min of ischemia and 60 min of
reperfusion were similar in saline and lipopolysaccharide-treated TLR4-def mice, suggesting
the inability of lipopolysaccharide to induce cardiac protection in the TLR4-def mice. In
contrast, similar to their WT controls (C57BL/6J), TLR2−/− mice treated with
lipopolysaccharide had improved LV function and reduced MI sizes (fig. 3). It is noteworthy
that the two strains of WT mice, TLR4-def and TLR2−/− mice all had the same baseline LV
function prior to I/R as demonstrated by LVDP and dP/dtmax in the Langendorff system
(table 2). Taken together, these data demonstrate that TLR4, not TLR2, specifically
mediates the lipopolysaccharide-induced cardiac protection against I/R injury.
MyD88, not Trif, is essential for the TLR4-mediated cardioprotection against I/R injury
MyD88 and Trif are two adaptors that are critical for TLR4 signaling and mediate activation
of NF-κB and interferon regulatory factor 3 (IRF3), respectively. To determine whether the
two signaling pathways control the TLR4-induced cardioprotection, we tested the
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lipopolysaccharide preconditioning effect in MyD88−/− and Trif−/− mice. Both MyD88−/−
and Trif−/− mice had the same baseline LV function compared to WT mice prior to I/R
(table 2). LV function was similarly impaired in the saline-treated MyD88−/− and Trif−/−
mice (fig. 4). Compared to the saline-treated Trif−/− animals, lipopolysaccharide-treated
Trif−/− mice had a significant improvement in LVDP and dP/dtmax, and reduced MI sizes
following I/R, a protective effect similar to that seen in the WT controls (WTBL6-LPS) (fig.
4). In contrast, lipopolysaccharide pretreatment failed to improve the LV function or reduce
MI size in MyD88−/− mice (fig. 4). These data suggest that MyD88, but not Trif, signaling
mediates the lipopolysaccharide-induced cardioprotection against I/R injury.
TLR4 activation induces nitric oxide production in a MyD88-dependent manner
TLR4 stimulation induces iNOS induction 7,21 and activates the nitric oxide-sGC signaling
pathway. To determine if iNOS-NO-sGC signaling mediates the TLR4-induced
cardioprotection, we tested whether lipopolysaccharide, at the dose of 0.1 mg/kg, induced
nitric oxide production. Nitric oxide has an extremely short life of a few ms in vivo, making
direct measurement of nitric oxide particularly challenging. Plasma nitrate and nitrite levels,
as a measure of N nitric oxide production, were measured at 24 h after saline or
lipopolysaccharide injection. As indicated in figure 5, lipopolysaccharide induced a 2.7-fold
increase in the plasma level of NOx of WTBL/6 mice (13.2 ± 1.0 vs. 36 ± 4.4 μM, P < 0.01)
and a 2.5-fold increase in WTBL/10 mice (14.6 ± 5.0 vs. 36.1 ± 6.9 μM, P < 0.05). TLR4 or
MyD88 deficiency resulted in an inability of lipopolysaccharide to increase the plasma
levels of NOx although the TLR4-def mice had a higher level of baseline NOx than that of
WT (C57BL/10) (P < 0.05). Moreover, iNOS−/− mice did not respond to lipopolysaccharide
with the plasma NOx at the baseline level of the saline group (fig. 5). Importantly, 1400W, a
highly selective and potent iNOS inhibitor 30, blocked NO induction in the
lipopolysaccharide-treat WT mice. These data suggest that a low dose of lipopolysaccharide
induces nitric oxide production in a TLR4- and MyD88-dependent manner and that either
iNOS genetic deletion or inhibition blocks nitric oxide production in response to
lipopolysaccharide in vivo.
iNOS is critical for the TLR4-mediated cardioprotection
We next tested the impact of iNOS genetic deletion or pharmacological inhibition on the
TLR4-mediated cardioprotection. As indicated in figure 6, iNOS genetic deletion (iNOS−/−)
abolished the lipopolysaccharide-induced cardiac preconditioning. LV function and MI size
were similar between the saline- and lipopolysaccharide-treated iNOS−/− mice (LVDP: 58.7
± 6.4% vs. 61.3 ± 5.6%; dP/dtmax: 68.6 ± 8.1% vs. 70.7±7.0%; MI sizes: 30.4 ± 4.1% vs.
28.8 ± 5.1%, n = 6) (fig. 6). On the other hand, iNOS inhibition by 1400W significantly
attenuated the ability of lipopolysaccharide to protect against I/R-induced LV dysfunction.
While lipopolysaccharide treatment still resulted in a partial improvement in LV function in
1400W-pretreated mice (WTBL/6-1400W-LPS) compared to the saline control (WTB/
6-1400W-Saline), the LV function recovery was significantly lower than that of the
lipopolysaccharide-treated mice without 1400W pretreatment (WTBL/6-LPS) (P < 0.01)
(fig. 6 A–B). 1400W pretreatment also blocked the lipopolysaccharide-induced MI reduction
(fig. 6 C–D). Taken together, this series of studies demonstrate that iNOS genetic deletion or
pharmacological inhibition blocks or inhibits the lipopolysaccharide-induced
preconditioning, suggesting that iNOS and nitric oxide contribute to the lipopolysaccharide-
induced and TLR4-mediated cardioprotection against I/R injury.
TLR4-mediated cardioprotection is sGC-dependent
Nitric oxide elicits its biological activity via either cGMP-dependent or cGMP-independent
mechanisms. Soluble guanylate cyclase (sGC) is the primary target of nitric oxide and a
heme-containing heterodimeric enzyme that is responsible for cGMP generation. The sGCα
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β heterodimer is considered to be the principal cardiovascular isoform. To determine if
TLR4-induced cardioprotection is sGC-dependent, we employed mice deficient in the
sGCα1 subunit 28. These mice have severely impaired sGC enzymatic activity that is not
activated by NO or synthetic sGC activator 28. As expected, as a downstream target of nitric
oxide, sGCα1 deficiency had no apparent effect on the ability of lipopolysaccharide to
enhance nitric oxide production. sGCα1−/− mice had a marked increase in NOx production
in response to lipopolysaccharide (P < 0.001) although these mice also had higher level in
their baseline NOx compared to the WT control mice (24.5 ± 2.5 μM vs.13.2 ±1.0 μM, P <
0.01) (fig. 5). Importantly, despite the robust nitric oxide production following the
lipopolysaccharide treatment, these sGCα1−/− mice were not protected by the
lipopolysaccharide-elicited preconditioning. As indicated in figure 7, sGCα1−/− treated with
lipopolysaccharide had the same level of LVDP and dP/dtmax, and same MI size as the
saline-treated sGCα1−/− controls. It is noteworthy that similar to other genetically modified
mice, sGCα1−/− mice had the same baseline LV function prior to ischemia as demonstrated
by LVDP and dP/dtmax (table 2).
DISCUSSION
The current study was designed to delineate the intracellular signaling pathway that leads to
the lipopolysaccharide-induced cardiac preconditioning against I/R injury. A small dose of
lipopolysaccharide (0.1 mg/kg) did not effect the baseline LV function as assessed by serial
echocardiography and LV pressure measurements, but it elicited a marked cardiac protective
effect against I/R. Using genetically modified mouse strains and an ex-vivo model of cardiac
I/R injury, we demonstrated that TLR4 mediated the lipopolysaccharide-elicited cardiac
protection and MyD88, but not Trif, was essential for the TLR4-induced protection. The
small dose of lipopolysaccharide also resulted in a significant increase in the plasma level of
nitrate/nitrite. The lipopolysaccharide-induced NOx production and cardiac protection were
abolished or significantly attenuated in iNOS−/− mice or in WT pretreated with an iNOS
inhibitor. While sGCα1−/− mice responded to lipopolysaccharide with a robust nitric oxide
production, they were not protected from I/R injury. Taken together, these data suggest that
TLR4 activation confers a potent cardiac protection against I/R injury via a MyD88-
dependent, but Trif-independent mechanism. Moreover, iNOS and sGCα1 are proven to be
essential for the TLR4-induced cardiac protection (fig. 8).
Cardiac preconditioning is a well-documented phenomenon where a brief treatment triggers
endogenous survival mechanisms that protect the heart against I/R injury. Classic ischemic
preconditioning, e.g., a brief period (e.g., 5 min) of repeated coronary artery occlusion,
protects the myocardium against subsequent lethal I/R injury 18. Inhaled anesthetics also
triggers cardiac preconditioning that improves cardiac function and reduced infarction sizes
19. Similarly, a few TLR ligands including lipopolysaccharide, monophosphoryl Lipid A
(MLA), and lipoteichoic acid (a TLR2 ligand) can trigger cardiac protection that mimics the
ischemic or anesthetic cardiac preconditioning 31–35. While lipopolysaccharide-induced
cardiac protection has been well documented 5,20,23,31,36–39, the exact mechanisms that
lead to the protection have not been fully understood. Administration of lipopolysaccharide
leads to a robust systemic production of various cytokines and chemokines, such as TNFα,
IL-1, and IL-6, and hemodynamic disturbance, which can impact on cardiac function. Given
the systemic responses following in vivo lipopolysaccharide administration, it is unclear
whether the observed cardiac benefits in lipopolysaccharide-treated animals are the direct
results of TLR4 signaling or due to other events secondary to systemic TLR4 activation. The
current study has clearly established that TLR4 signaling mediates the lipopolysaccharide-
induced cardioprotective effect.
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We also demonstrate that the TLR4-mediated preconditioning is MyD88-dependent but
Trif-independent. These finding appear consistent with our previous in vitro finding that in
isolated cardiomyocytes, direct activation of TLR4 by lipopolysaccharide confers a marked
survival benefit in cardiomyocytes against apoptotic cell death during hypoxia and serum
deprivation. The TLR4-induced cell survival pathway is mediated via MyD88 21. MyD88 is
a key adaptor protein that is critical for transducing signals from all TLR family members
2,40–42, except TLR3, and interleukin-1 receptor family members. MyD88 signals via
IRAK-1 and other downstream kinases including IKKβ and IκB, eventually leading to the
activation of NF-κB and inflammatory cytokine production 3. On the other hand, Trif is a
key adaptor protein responsible for TLR3 and TLR4 signaling pathways that respond to viral
and bacterial stimulation and result in the production of type I interferons including IFNα,
IFNβ, and other IFNs 4. Stimulation of type I interferon pathways leads to induction of a
specific set of genes including chemokines (e.g., CXCL10) 43 and anti-microbial/antiviral
response genes 44. The detailed mechanisms by which each of the signaling component lead
to the cardioprotection seen in lipopolysaccharide-treated animals need to be further
investigated. Nevertheless, the present finding strongly suggests that TLR4-MyD88
signaling, upon activated, triggers a potent survival mechanism that protects the heart
against I/R injury (fig. 8).
NOS and nitric oxide have been implicated as a key intracellular mediator responsible for
both ischemic preconditioning and anesthetic preconditioning 45,46. iNOS, the inducible
form of NOS, is considered essential for the late phase of ischemic preconditioning in an in
vivo model of I/R injury 45. Moreover, over-expression of iNOS is found sufficient to
protect myocardium from I/R injury 47. Interestingly, NOS1 or endothelial NOS, but not
iNOS, has been proposed as the trigger for the isoflurane-induced preconditioning in a rabbit
model of I/R injury 46. Our finding that TLR4-MyD88 signaling is required for nitrate/nitrite
production in response to a preconditioning dose of lipopolysaccharide and that iNOS
genetic deletion as well as pharmacological inhibition attenuate the TLR4-mediated cardiac
preconditioning strongly suggest that iNOS- nitric oxide is the downstream effector of TLR4
signaling leading to the lipopolysaccharide-elicited preconditioning benefit against I/R. This
is consistent with a previous study by Xi and colleagues who reported that monophosphoryl
lipid A-induced preconditioning was abolished in iNOS−/− mice 32. The notion that cardiac
TLR4 is directly activated by lipopolysaccharide and subsequently leads to an iNOS-
dependent cardiac protection against I/R injury is supported by our previous finding that
TLR4 activation in isolated cardiomyocytes leads to a direct anti-apoptotic survival pathway
that is dependent on endogenous iNOS 21,22. It is noteworthy that while the selective iNOS
inhibitor 1400W completely inhibited the increase in the nitrate/nitrite production in the
lipopolysaccharide-treated mice, it only partially blocked the lipopolysaccharide-elicited LV
functional improvement. These may suggest that in addition to nitric oxide, other factor(s)
may also contribute to the TLR4-induced and iNOS-dependent cardiac protection.
Nitric oxide may confer myocardial protection by cGMP-dependent as well as cGMP-
independent mechanisms. For example, nitric oxide inhibits caspase-3 activity via S-
nitrosylation and thus may promote cell survival in a sGC/cGMP-independent manner 48.
On the other hand, nitric oxide can bind to the heme moiety of sGC and activate the enzyme
to generate cGMP. sGC is a main downstream effector of nitric oxide and responsible for
many nitric oxide-elicited biological effects. Here we demonstrate that the TLR4-mediated
cardioprotection against I/R injury is indeed dependent on sGCα1. Mice deficient in sGCα1
completely lost the protection conferred by lipopolysaccharide despite sGCα1−/− mice
responded normally to lipopolysaccharide with a robust nitric oxide production.
Another endogenous survival pathway, namely phosphatidylinositol-3 kinase (PI3 kinase)/
Akt, has been proposed for the lipopolysaccharide-induced cardiac protective effect. We
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have previously demonstrated that PI-3 kinase/Akt, extracellular signal-regulated kinase 1/2
(ERK1/2), and IκB kinase β (IKKβ) pathways all contribute to the lipopolysaccharide-
induced anti-apoptotic survival effect in cardiomyocytes 22. Moreover, in vivo, the cardiac
benefit of lipopolysaccharide against I/R injury is abolished by a PI-3 kinase inhibitor or in
transgenic mice expressing inactive Akt mutant 39.
Some limitations of the present study should be acknowledged. First, using the in vivo
model, we were not able to determine whether the cardiac ischemic protection in the
lipopolysaccharide-treated mice is result of direct myocardial TLR4 activation. While our
previous in vitro data suggest a direct survival benefit of TLR4-MyD88 signaling in
cardiomyocytes 22, other approaches will be needed, such as cardiac specific TLR4 knock-
out or chimera model 17, to define the specific role of cardiac TLR4 in myocardial
protection against I/R injury. Second, lipopolysaccharide is a potent pyrogenic agent and
thus clearly not a good candidate to test its therapeutic value in attenuating I/R injury.
Nonpyrogenic TLR4 agonists will be needed to further test the efficacy of TLR4 signaling
to protect against I/R injury. Finally, I/R injury model in this study was developed in
isolated hearts perfused in a Langendorff apparatus. While the ex-vivo system offers certain
advantages, such as relative ease to perform, the ability to control left ventricular pre- and
after-load, and the ability to continuously measure cardiac contractile function throughout I/
R period, the heart is perfused with cell- and serum-free buffer and thus certain neuro-
hormonal factors in response to I/R could have been omitted. In this regard, in vivo I/R
injury model involving coronary artery occlusion offers clear advantage 49–51. Both
experimental models have been widely used by numerous laboratories including
ours10,16,17.
Nevertheless, the present study establishes that TLR4 activation confers a potent cardiac
protection against I/R injury via a MyD88-dependent, but Trif-independent mechanism.
Moreover, iNOS and sGC 1 are proven to be essential for the TLR4-induced cardiac
protection (fig. 8). Our study suggests that selective targeting TLR4-MyD88 signaling may
represent a novel therapeutic strategy for cardioprotection against ischemic myocardial
injury.
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Fig. 1. Representative M-mode echocardiograms of WT mice 24 h after normal saline or
lipopolysaccharide injection
Echocardiography was performed 24 h after normal saline (A) or 0.1 mg/kg of
lipopolysaccharide (LPS) (B) was administered to wild-type C57BL/6J mice by
intraperitoneal injection. M-mode echocardiographic measurements confirmed normal left
ventricular (LV) contractile function and normal LV sizes in both saline- and
lipopolysaccharide-treated mice. PM = papillary muscle; AW = anterior wall; PW =
posterior wall.
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Fig. 2. Lipopolysaccharide-elicited preconditioning against I/R injury is present in WT, but not
in TLR4-def mice
Wild-type C57BL/10ScSn strain (WTBL/10) and Toll-like receptor 4-deficient (TLR4-def )
mice were treated with normal saline or 0.1 mg/kg of lipopolysaccharide (LPS)
intraperitoneally. Twenty-four hours later, mouse hearts were isolated and perfused in a
Langendorff apparatus. After 30 min of perfusion, the hearts were subjected to 30 min of no-
flow global ischemia followed by 60 min of reperfusion as described in the Methods. Left
ventricular developed pressure (LVDP) and dP/dtmax were continuously measured and
recorded. A. LVDP and B. dP/dtmax , expressed as percentage of the baseline. Each data
point and error bar in A–B represents the mean ± SE. The number of mice in each group is
as follows: WTBL/10-Saline: 9, WTBL/10-LPS: 8, TLR4-def-Saline: 6, TLR4-def-LPS: 6. *P
< 0.05, **P < 0.01. NS, not significant. C. Myocardial infarction (MI) sizes expressed as the
percentage of LV area. The horizontal lines represent the mean ± SE. *P < 0.05. D.
Representative heart slices after triphenyltetrazolium chloride staining from WT and
TLR4-def mice. Viable myocardium was stained red and infarcted myocardium white.
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Fig. 3. TLR2 deficiency has no impact on lipopolysaccharide-elicited preconditioning against I/R
injury
Wild-type C57BL/6J (WTBL/6) and Toll-like receptor 2 knockout (TLR2−/−) mice were
treated with normal saline or 0.1 mg/kg of lipopolysaccharide (LPS) intraperitoneally.
Twenty-four hours later, mouse hearts were isolated and perfused in a Langendorff system.
After 30 min of perfusion, the hearts were subjected to 30 min of no-flow global ischemia
followed by 60 min of reperfusion. A. Left ventricular developed pressure (LVDP); B. dP/
dtmax, expressed as percentage of the baseline. Each data point and error bar in A–B
represents the mean ± SE. The number of mice in each group is as follows: WTBL/6-Saline:
10, WTBL/6-LPS: 11, TLR2−/−-Saline: 8, TLR2−/−-LPS: 8. **P < 0.01. C. Myocardial
infarction (MI) size as expressed as the percentage of left ventricle area (LV). The horizontal
lines represent the mean ± SE. **P < 0.01. D. Representative heart slices after
triphenyltetrazolium chloride staining from WT and TLR2−/− mice. Viable myocardium was
stained red and infarcted myocardium appeared white.
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Fig. 4. Lipopolysaccharide-elicited preconditioning against I/R injury is MyD88-dependent, but
Trif-independent
Wild-type C57BL/6J (WTBL/6), Myeloid differentiation factor 88 knockout (MyD88−/−),
and TIR-domain-containing adaptor protein inducing interferon-β–mediated transcription-
factor knockout (Trif−/−) mice were treated with normal saline or 0.1 mg/kg of
lipopolysaccharide (LPS) intraperitoneally. Twenty-four hours later, mouse hearts were
isolated and perfused in a Langendorff system. After 30 min of perfusion, the hearts were
subjected to 30 min of no-flow global ischemia followed by 60 min of reperfusion. A. Left
ventricular developed pressure (LVDP); B. dP/dtmax, expressed as percentage of the
baseline. Each data point and error bar in A–B represents the mean ± SE. The number of
mice in each group is as follows: WTBL/6-Saline: 10, WTBL/6-LPS: 11, Trif−/−-Saline: 6,
Trif−/−-LPS: 6, MyD88−/−-Saline: 7, MyD88−/−-LPS: 7. **P < 0.01. NS, not significant. C.
Myocardial infarction (MI) size as expressed as the percentage of left ventricle area (LV).
The long and short horizontal lines represent the mean ± SE. *P < 0.05, **P < 0.01, NS,
not-significant. D. Representative heart slices after triphenyltetrazolium chloride staining
from Trif−/− and MyD88−/− mice. Viable myocardium was stained red and infarcted
myocardium appeared white.
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Fig. 5. Effect of low dose lipopolysaccharide on the plasma concentrations of nitrite/nitrate in
different mouse strains
Mice were treated with normal saline or 0.1 mg/kg of lipopolysaccharide (LPS)
intraperitoneally. 1400W (20 mg/kg) was given to wild-type C57BL/6J (WTBL/6) mice 2
hours before saline or LPS administration. Twenty-four hours later, blood was collected and
plasma prepared. Nitrite and nitrate were measured using a fluorometric assay. Each error
bar represents the mean ± SE. The number shown in each bar represents the sample size in
the group. *P < 0.05, **P < 0.01, ***P < 0.001. iNOS−/− = inducible nitric-oxide synthase
knockout; 1400W = N-(3-(Aminomethyl)benzyl)acetamidine; MyD88−/− = myeloid
differentiation factor 88 knockout; sGC−/− = soluble guanylate cyclase knockout; TLR4-def
= toll-like receptor 4-deficient; WTBL/6 = wild-type C57BL/6J; WTBL/10 = wild-type
C57BL/10ScSn.
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Fig. 6. Effect of iNOS deletion or inhibition on the lipopolysaccharide-elicited preconditioning
against I/R injury
Wild-type C57BL/6J (WTBL/6), WTBL/6 pre-treated with 1400W, and inducible nitric-
oxide synthase knockout (iNOS−/−) mice were treated with normal saline or 0.1 mg/kg of
lipopolysaccharide (LPS) intraperitoneally. 1400W was given at the dose of 20 mg/kg to
WTBL/6 mice 2 hours before saline or LPS administration. Twenty-four hours later, mouse
hearts were isolated and perfused in a Langendorff system and subjected to the I/R protocol.
A. Left ventricular developed pressure (LVDP); B. dP/dtmax. expressed as percentage of the
baseline. Each data point and error bar in A–B represents the mean ± SE. The number of
mice in each group is as follows: iNOS−/−-Saline: 7, iNOS−/−-LPS: 8, WTBL/6-1400W-
Saline: 7, WTBL/6-1400W-LPS: 7. **P < 0.01. NS, not-significant. C. Myocardial
infarction (MI) size as expressed as the percentage of left ventricle area (LV). The long and
short horizontal lines represent the mean ± SE. **P < 0.01. D. Representative heart slices
after triphenyltetrazolium chloride staining from iNOS−/− and WT mice pretreated with
1400W. Viable myocardium was stained red and infarcted myocardium appeared white.
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Fig. 7. Effect of sGC-deficiency on the lipopolysaccharide-elicited preconditioning against I/R
injury
Soluble guanylate cyclase knockout (sGCα1−/−) female mice were treated with normal
saline or 0.1 mg/kg of lipopolysaccharide (LPS) intraperitoneally. Twenty-four hours later,
mouse hearts were isolated and perfused in a Langendorff system. After 30 min of
perfusion, the hearts were subjected to 30 min of no-flow global ischemia followed by 60
min of reperfusion. A. Left ventricular developed pressure (LVDP); B. dP/dtmax, expressed
as percentage of the baseline. Each data point and error bar in A–B represents the mean ±
SE. The number of mice in each group is as follows: WTBL/6-Saline: 10, WTBL/6-LPS: 11,
sGCα1−/−-Saline: 10, sGCα1−/−-LPS: 11. *P < 0.05, **P < 0.01, NS, not-significant. C.
Myocardial infarction (MI) size as expressed as the percentage of left ventricle area (LV).
The long and short horizontal lines represent the mean ± SE. *P < 0.05, **P < 0.01. D.
Representative heart slices after triphenyltetrazolium chloride staining from sGCα1−/− mice.
Viable myocardium was stained red and infarcted myocardium white.
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Fig. 8. Proposed signaling pathway for the TLR4-mediated cardiac protection against I/R
TLR4 activation by its ligand such as LPS leads to iNOS induction and increased NO
production through a MyD88-dependent mechanism. NO protects myocardium via sGC- and
cGMP/PKG-dependent mechanisms. 1400W, a potent iNOS inhibitor, blocks LPS/TLR4-
induced NO production and inhibits its cardiac protection. In contrast, Trif is not required
for the TLR4-mediated cardiac protection. LPS = lipopolysaccharide; iNOS = inducible
nitric-oxide synthase; MyD88 = myeloid differentiation factor 88; sGC = soluble guanylate
cyclase; PKG = protein kinase G; TLR = toll-like receptor; Trif = TIR-domain-containing
adaptor protein inducing interferon-β–mediated transcription factor.
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Table 1
Serial Echocardiographic Measurements before and 24 Hours after Normal Saline or Lipopolysaccharide
Administration
Saline LPS (0.1 mg/kg)
Baseline 24 h Baseline 24 h
HR, beats/m 686 ± 12 698 ± 16 670 ± 20 675 ± 16
FS, % 49.8 ± 1.4 52.8 ± 1.9 51.7 ± 1.1 52.1 ± 1.2
LVEF, % 82.4 ± 1.3 85.1 ± 1.7 84.0 ± 1.0 84.5 ± 0.9
LVIDED, mm 3.1 ± 0.1 3.0 ± 0.1 3.2 ± 0.1 3.0 ± 0.0
LVIDES, mm 1.6 ± 0.1 1.4 ± 0.1 1.5 ± 0.1 1.5 ± 0.0
Values are mean ± SE, n = 5/group. FS = fractional shortening; HR = heart rate; LPS = lipopolysaccharide; LVEF = left ventricular ejection
fraction; LVIDED = left ventricular end-diastolic internal diameter; LVIDES = left ventricular end-systolic internal diameter.
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